pyrroles has been researched along with brivanib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; Chao, S; D'Arienzo, C; Derbin, G; Fargnoli, J; Fura, A; Hunt, JT; Jeyaseelan, R; Kamath, A; Kim, SH; Kukral, D; Leavitt, K; Leith, L; Lombardo, LJ; Marathe, P; Mathur, A; Mortillo, S; Qian, L; Vyas, V; Wautlet, B; Wei, D; Wu, LI; Zhang, YZ; Zheng, X | 1 |
| Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; D'Arienzo, C; Derbin, G; Fan, J; Fargnoli, J; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Marathe, P; Mortillo, S; Qian, L; Robl, JA; Shi, Z; Wautlet, BS; Wei, D; Wu, L; Zhang, Y; Zheng, X | 1 |
| Bhide, R; D'Arienzo, C; Fargnoli, J; Kamath, AV; Marathe, PH; Zhang, Y | 1 |
| Barrish, JC; Bhide, RS; Cai, ZW; Fargnoli, J; Galbraith, S; Henley, BJ; Hunt, JT; Jeyaseelan, R; Krishnan, B; Kukral, D; Lewin, AC; Lombardo, LJ; Malone, H; Mortillo, S; Wautlet, BS | 1 |
| Fargnoli, J; Jordan, VC; Kim, HR; Klein-Szanto, AJ; Li, T; Oseni, S; Patel, RR; Pyle, JR; Ross, EA; Sengupta, S; Zhu, F | 1 |
| Fischer, BS; Gan, J; Ganapathi, R; Gong, J; Iyer, R; Masson, E; Mekhail, T; Patricia, D; Pursley, J; Williams, D | 1 |
| Dempke, WC; Zippel, R | 1 |
| Baudelet, C; Finn, RS; Harris, R; Ismail, F; Karwal, M; Kim, JS; Li, RK; Park, JW; Raoul, JL; Thomas, M; Walters, I | 1 |
| Diaz-Padilla, I; Siu, LL | 1 |
| Abbas, A; Jones, H; Kingston, GT; Zurek, A | 1 |
| Chang, AY; Wang, M | 1 |
| Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M | 1 |
| Kalyan, A; Kulik, L; Nimeiri, H | 1 |
3 review(s) available for pyrroles and brivanib
| Article | Year |
|---|---|
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Topics: Alanine; Clinical Trials as Topic; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Brivanib alaninate for cancer.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
2 trial(s) available for pyrroles and brivanib
| Article | Year |
|---|---|
Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Aged; Alanine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Pyrroles; Triazines | 2010 |
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrroles; Treatment Outcome; Triazines; Tumor Burden | 2011 |
8 other study(ies) available for pyrroles and brivanib
| Article | Year |
|---|---|
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Prodrugs; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Carcinoma; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Intestines; Liver; Lung Neoplasms; Mice; Microsomes; Molecular Structure; Prodrugs; Protein Kinase Inhibitors; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Solubility; Stereoisomerism; Triazines; Vascular Endothelial Growth Factor Receptor-2; Water; Xenograft Model Antitumor Assays | 2008 |
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Topics: Administration, Oral; Alanine; Animals; Antineoplastic Agents; Biological Availability; Brain; Caco-2 Cells; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Injections, Intravenous; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Pyrroles; Rats; Solubility; Tissue Distribution; Triazines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Topics: Alanine; Animals; Antigens, CD34; Cell Line, Tumor; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Laminin; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Proteoglycans; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Time Factors; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Random Allocation; Receptor, Fibroblast Growth Factor, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transplantation, Heterologous; Triazines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Malignant peripheral nerve sheath tumour presenting as a pneumothorax.
Topics: Adult; Alanine; Antineoplastic Agents; Fatal Outcome; Humans; Male; Nerve Sheath Neoplasms; Peripheral Nervous System Neoplasms; Pneumothorax; Pyrroles; Radiography, Thoracic; Triazines | 2011 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |